Introduction to Codexis Participation
Codexis, Inc. (NASDAQ: CDXS), a prominent name in the field of enzymatic solutions, is excited to announce its participation in the TD Cowen 45th Annual Health Care Conference. This prestigious event is set to take place from March 3 to March 5, and it provides a platform for industry leaders to connect, share insights, and discuss the future of health care innovations.
Event Details
Management from Codexis is scheduled to engage in a fireside chat on the second day of the conference, March 4. This session will begin at 1:10 pm ET and promises to be an insightful discussion about the company's vision and advancements in enzymatic solutions for therapeutics manufacturing.
Accessing the Conference
For those who wish to follow the conversation live, there will be a webcast available in the Investor Relations section of the Codexis website. The webcast aims to ensure that stakeholders and interested parties can stay updated on the vital information discussed at this key event. Additionally, a replay of the webcast will be accessible for 90 days following the event, offering an opportunity for those who cannot attend to catch up on the important insights shared.
About Codexis
Codexis is at the forefront of enzymatic solutions, specializing in manufacturing processes that promise efficiency and scalability. Through its proprietary CodeEvolver technology, Codexis is revolutionizing the development of high-performance enzymes that tackle significant challenges in the production of small molecule pharmaceuticals and nucleic acids.
Innovative Manufacturing Platforms
A key area of development for Codexis is its ECO Synthesis™ manufacturing platform. This groundbreaking project is focused on enabling the scalable production of RNAi therapeutics using enzymatic methods. By leveraging its unique enzymes, Codexis aims to enhance manufacturing processes, which are critical in fostering advancements in healthcare.
Importance of Efficiency
With a commitment to innovation, Codexis emphasizes improvements such as increased yields, decreased energy consumption, reduced waste output, and heightened sensitivity in genomic and diagnostic applications. These improvements are essential in optimizing therapeutic pathways and ensuring high-quality outcomes in drug manufacturing.
Contact Information
For investors and media seeking more information about Codexis, the company’s investor relations contact is Carrie McKim, reachable at (336) 608-9706. For media inquiries, Lauren Musto is available at (650) 421-8205. Interested parties can reach out via email at ir@codexis.com and media@codexis.com.
Frequently Asked Questions
What is the TD Cowen Health Care Conference?
The TD Cowen Health Care Conference is an event where leaders in healthcare come together to discuss innovations, trends, and insights in the industry.
When will Codexis participate in the conference?
Codexis will participate on March 4, during a fireside chat scheduled for 1:10 PM ET.
How can I access the Codexis webcast?
The webcast can be accessed through the Investor Relations section of the Codexis website.
What technologies does Codexis focus on?
Codexis specializes in enzymatic solutions geared towards therapeutics manufacturing, employing its proprietary CodeEvolver technology.
Who can I contact for more information?
For inquiries, you can contact Carrie McKim at (336) 608-9706 for investor concerns or Lauren Musto at (650) 421-8205 for media-related questions.
